Compounds > fulvestrant
Page last updated: 2024-08-26

fulvestrant and afimoxifene

fulvestrant has been researched along with afimoxifene in 120 studies

Research

Studies (120)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's31 (25.83)18.2507
2000's46 (38.33)29.6817
2010's36 (30.00)24.3611
2020's7 (5.83)2.80

Authors

AuthorsStudies
Abrams, T; Baird, J; Burks, HE; Firestone, B; Gaither, LA; Hamann, LG; He, G; Kim, S; Kirby, CA; Lombardo, F; Macchi, KJ; McDonnell, DP; Mishina, Y; Norris, JD; Nunez, J; Peukert, S; Springer, C; Sun, Y; Thomsen, NM; Tiong-Yip, CL; Tria, GS; Wang, C; Wang, J; Yu, B1
Demizu, Y; Fujisato, T; Kanda, Y; Kurihara, M; Makishima, M; Misawa, T; Naito, M; Ohoka, N; Sekino, Y; Shoda, T; Yorioka, M1
Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, SP; Hager, JH; Heyman, R; Joseph, JD; Kahraman, M; Kaufman, J; Lai, A; Lee, K; Liu, N; Nagasawa, JY; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND1
Dong, C; Hu, Z; Huang, J; Huang, S; Li, Y; Xiao, Y; Zhang, J; Zhang, S; Zhou, HB1
Hashimoto, Y; Makishima, M; Nanjyo, S; Noguchi-Yachide, T; Ohgane, K; Yoshioka, H1
Chen, H; Dubrovyskyii, O; Dye, K; Gordon-Blake, J; Gutgesell, LM; He, D; Hollas, M; Huang, F; Lasek, AW; Lee, S; Li, Y; Lu, Y; Rosales, CI; Shen, Z; Thatcher, GRJ; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J1
Boudreau, MW; Fan, TM; Hergenrother, PJ; Mulligan, MP; Shapiro, DJ1
Cao, Y; Guo, B; Kong, D; Lu, Z; Meng, X; Yang, Y; Zhang, D1
Catherino, WH; Jordan, VC; Wolf, DM1
Potter, BV; Purohit, A; Reed, MJ; Roberts, CJ; Williams, GJ1
DeLuise, M; Hu, XF; Parisot, JP; Sutherland, RL; Wakeling, A; Zalcberg, JR1
Cavaillès, V; Danielian, PS; Dauvois, S; Parker, MG1
Anderson, E; Bell, J; DeFriend, DJ; Howell, A; Mansel, RE; West, CM; Wilks, DP1
Dauvois, S; Parker, MG; White, R1
Bouchoux, F; Brémaud, J; Hameau, MC; Lucas, D; Moratille, C; Nique, F; Philibert, D; Teutsch, G; Van de Velde, P; Viet, S1
Choudhary, Q; Croxtall, JD; Emmas, C; Flower, RJ; White, JO1
Brünner, N; Clarke, R; Coopman, P; Derocq, D; Garcia, M; Rochefort, H1
Bei, M; Brünner, N; Clarke, R; Frandsen, TL; Holst-Hansen, C; Lippman, ME; Thompson, EW; Wakeling, AE1
Clerico, L; de Cupis, A; Favoni, RE; Ferrera, A; Noonan, D; Pirani, P1
Addeo, R; Altucci, L; Battista, T; Bonapace, IM; Bresciani, F; Cancemi, M; Cicatiello, L; Germano, D; Pacilio, C; Salzano, S; Weisz, A1
Blair, HC; Jordan, SE; McDonald, JM; McKenna, MA; Williams, JP1
Katzenellenbogen, BS; Montano, MM1
Logie, C; Nichols, M; Rientjes, JM; Stewart, AF1
Brown, M; DiRenzo, J; Dowdy, SF; Ewen, ME; Hinds, PW; Ladha, MH; Lin, N; Miller, SJ; Neuman, E; Pestell, RG; Upton, TM1
Chambon, P; Feil, R; Metzger, D; Wagner, J1
Ali, S; Coombes, RC; Pace, P; Suntharalingam, S; Taylor, J1
Bonde, SK; Gori, F; Hofbauer, LC; Rickard, DJ; Riggs, BL; Spelsberg, TC1
Jensen, EV; Knabbe, C; Müller, V1
Assikis, VJ; Bilimoria, MM; Chen, Z; England, GM; Jordan, VC; Muenzner, HD1
Jordan, VC; Levenson, AS; Tonetti, DA1
Anderson, KC; Chauhan, D; Ogata, A; Teoh, G; Treon, SP; Urashima, M; Webb, IJ1
Funder, JW; Logie, C; Myles, K; Nichols, M; Stewart, AF1
Huynh, H; Pollak, M1
Resnick, EM; Schreihofer, DA; Shupnik, MA; Soh, AY1
DeGeorge, GL; Gadd, SL; Harnagea-Theophilus, E; Knight-Trent, AH; Miller, MR1
Ehlers, EM; Schubert, C1
Clarke, R; Lavigne, MC; Ramwell, PW1
Christensen, DJ; Fowlkes, DM; McDonnell, DP; Nagel, SC; Norris, JD; Paige, LA; Wijayaratne, AL1
Birchmeier, W; Lichtner, RB; Parczyk, K; Schneider, MR1
Allegretto, EA; Mancini, MA; Mancini, MG; Patel, K; Smith, CL; Stenoien, DL1
Ho, SM; LaSpina, M; Lau, KM; Long, J1
Bentrem, DJ; Jordan, VC; Liu, H; MacGregor Schafer, J; Zapf, JW1
Fisher, PW; Gowen, M; Nadeau, DP; Nuttall, ME; Stroup, GB; Suva, LJ1
Conrad, SE; Varma, H1
Dutertre, M; Mancini, MA; Mancini, MG; O'Malley, BW; Patel, K; Smith, CL; Stenoien, DL1
Kim, J; Nardulli, AM; Petz, LN; Potthoff, SJ; Wood, JR; Ziegler, YS1
Gaido, K; Pallaroni, L; Safe, S; Stoner, M; Yoon, K1
Parker, MG; Soulez, M1
Ali, S; Bates, GJ; Chen, D; Coombes, RC; Egly, JM; Epstein, RJ; Fuller-Pace, FV; Pace, PE; Sarwar, N; Taylor, J; Thirunuvakkarasu, V; Washbrook, E1
Jordan, VC; Lee, ES; Takei, H1
Calligé, M; Chailleux, C; Giamarchi, C; Richard-Foy, H; Rochaix, P; Trouche, D1
Kim, K; Safe, S; Saville, B; Thu, N1
Bianco, NR; Montano, MM; Perry, G; Smith, MA; Templeton, DJ1
Abrams, J; Deighton-Collins, S; Koide, A; Koide, S; Martinez, A; Schwartz, JA; Skafar, DF; Zhao, C1
Chaouat, M; Forgez, P; Gompel, A; Jacob, D; Perrot, JY; Rostène, W; Somaï, S1
Gougelet, A; Maillard, S; Marsaud, V; Renoir, JM1
Carroll, JS; Daly, RJ; Lynch, DK; Musgrove, EA; Renoir, JM; Sarcevic, B; Sutherland, RL; Swarbrick, A1
Klinge, CM; Risinger, KE; Thomas, PB1
Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jordan, N; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Wakeling, AE1
Edwards, EA; Fulthorpe, R; Liss, SN; Wang, DY1
Buck, MB; Knabbe, C; Pfizenmaier, K1
Barrón-González, A; Castro Romero, I1
Birnbaum, D; Cohen, PA; Danis, E; Duchesne, MJ; Magnino, F; Nguyen, C; Pinloche, S; Pons, M; Theillet, C; Vendrell, JA1
Balaguer, P; Bonnet, S; Cavaillès, V; Duong, V; Escande, A; Margueron, R; Vignon, F1
Barrett, JT; Delk, JN; Gaddy, VT; Kallab, AM; Porter, AG; Schoenlein, PV1
Bhatnagar, S; Blankenship, KA; Brey, DM; Keynton, RS; Klinge, CM; Noisin, EL; Risinger, KE; Sumanasekera, WK; Zhao, L1
Arreguin-Arevalo, JA; Nett, TM1
Berndtson, AK; Nephew, KP; Reed, CA1
Izewska, P; Jankevics, H; Leufgen, K; Pick, H; Prummer, M; Vogel, H1
Body, JJ; Chaboteaux, C; Duvillier, H; Journe, F; Laurent, G; Magne, N1
Clarke, R; Dai, P; Lou, MA; Lu, JF; Nazarov, V; Wong, LJ1
Kofoed, EM; Li, L; Padron, A; Schaufele, F1
Cochrum, RK; Klinge, CM; Riggs, KA; Watts, MB; Wickramasinghe, NS1
Fritah, A; Redeuilh, G; Sabbah, M1
Asselin, E; Bélanger, G; Boucher, V; Déry, MC; Leblanc, K; Parent, S; Sexton, E1
Altobelli, G; Biglia, N; Cicatiello, L; Cimino, D; De Bortoli, M; Friard, O; Fuso, L; Ponzone, R; Ravo, M; Scafoglio, C; Sismondi, P; Weisz, A1
Bracke, M; Comhaire, F; De Wever, O; Dhooge, W; Eertmans, F; Kaufman, JM1
Cheng, J; Shapiro, DJ; Yu, DV; Zhou, JH1
Carcel-Trullols, J; Evans, TT; Higuchi, M; Mizumachi, T; Naito, A; Xie, CH1
Jankevics, H; Pick, H; Vogel, H1
Adamson, AD; Davis, JR; Friedrichsen, S; Harper, CV; Mullins, JJ; Semprini, S; White, MR1
Blackmore, PF; Chatterjie, N; Dobrydneva, Y; Fichandler, CE; Fitzgerald, MC; Morrell, MM; Trebley, JP; Weatherman, RV1
Bieche, I; Cohen, PA; Dumontet, C; Ghayad, SE; Lidereau, R; Spyratos, F; Treilleux, I; Vendrell, JA1
Aiyar, S; Fan, P; Kim, TH; Li, Y; Santen, RJ; Wang, JP; Yue, W1
Dougherty, SM; Klinge, CM; Li, Y; Manavalan, TT; Riggs, KA; Wickramasinghe, NS1
Cheng, P; Hershberger, PA; Kanterewicz, B; Liu, Y; McCarty, KS; Nichols, M1
Dougherty, SM; Ivanova, MM; Klinge, CM; Mazhawidza, W1
El Gebeily, G; Fiset, C1
Fan, M; Long, X; Nephew, KP1
Ashworth, A; Geyer, F; Gillett, C; Grigoriadis, A; Iorns, E; Lambros, M; Lopez-Garcia, MA; Mackay, A; Marchio, C; Natrajan, R; Pearson, A; Reis-Filho, JS; Sharpe, R; Turner, N; Tutt, A1
Goldstein, RE; Klinge, CM; Kumar, A1
Bystricky, K; Dalvai, M1
Anaganti, S; Fernandez-Cuesta, L; Hainaut, P; Olivier, M1
Bystricky, K; Caze-Subra, S; Kocanova, S; Mazaheri, M1
Ashcroft, FJ; Jones, ED; Mancini, MA; Mikic, I; Newberg, JY1
Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N1
Ceron, CS; Desta, Z; Flockhart, DA; Montenegro, MF; Salgado, MC; Tanus-Santos, JE1
Brodie, A; Carboni, JM; Finckenstein, FG; Gottardis, MM; Greer, A; Haluska, P; Harrington, SC; Hou, X; Huang, F; Macedo, LF; Reeves, KA1
Hojo, Y; Kawato, S; Kimoto, T; Ogiue-Ikeda, M; Shimohigashi, Y; Tanabe, N; Yoshino, H1
Kazmin, D; McDonnell, DP; Wardell, SE1
Badia, E; Balaguer, P; Busson, M; Cavailles, V; Docquier, A; Lapierre, M; Pujol, P1
Aboagye, EO; Ali, S; Lake, MC; Nguyen, QD1
Hoffman, KL; Lerner, SP; Smith, CL1
Biswas, PK; Chakraborty, S; Levenson, AS1
Cheung, V; Clyne, CD; Knower, KC; Lazarus, KA; To, SQ1
de Haan, LH; Ederveen, AG; Evers, NM; Groten, JP; Houtman, R; Melchers, D; Rietjens, IM; van den Berg, JH; Wang, S1
Kanomata, N; Kurebayashi, J; Moriya, T; Shimo, T; Yamashita, T1
Munster, PN; Park, J; Raha, P; Thomas, S; Thurn, KT1
Hui, Y; Kurogi, K; Liu, MC; Luo, L; Sakakibara, Y; Suiko, M; Zhang, L; Zhou, C1
Badia, E; Balaguer, P; Boulahtouf, A; Boulle, N; Cavaillès, V; Cristol, JP; Lauret, C; Morena, M1
Andrews, P; Carter, B; Gai, L; Kao, KR; Popadiuk, C; Tzenov, YR; Voisey, K; Whelan, K1
Cazzulino, AS; Denny, CA; Martinez, R; Tomm, NK1
Kim, JE; Livezey, M; Mao, C; Shapiro, DJ1
Acconcia, F; Bianchi, F; Busonero, C; Leone, S1
Alhusban, A; Alkhalifa, AE; Ayoub, NM; Ibrahim, DR1
Bruinsma, ES; Emch, MJ; Goetz, MP; Hawse, JR; Ingle, JN; Jones, CJ; Subramaniam, M1
Akerstrom, VL; Bratton, MR; Guo, S; Liu, J; Ma, P; Ma, Y; Miele, L; Pannuti, A; Skripnikova, EV; Wang, G; Wiese, TE; Yuan, C; Zhang, C; Zhang, Q; Zheng, S; Zhong, Q1
Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J1
Bai, C; Luo, G; Ren, S; Wu, S; Xiang, H; Zhu, M1
Baecker, D; Gaggia, F; Gust, R; Kalchschmid, C; Knox, A; Manzl, C; Schuster, D1

Other Studies

120 other study(ies) available for fulvestrant and afimoxifene

ArticleYear
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
    Journal of medicinal chemistry, 2018, 04-12, Volume: 61, Issue:7

    Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Drug Design; Drug Discovery; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Mice; Mice, Nude; Rats; Rats, Sprague-Dawley; Rats, Wistar; Selective Estrogen Receptor Modulators; Thiophenes; Xenograft Model Antitumor Assays

2018
Design and synthesis of novel selective estrogen receptor degradation inducers based on the diphenylheptane skeleton.
    MedChemComm, 2017, Jan-01, Volume: 8, Issue:1

    Topics:

2017
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.
    ACS medicinal chemistry letters, 2019, Jan-10, Volume: 10, Issue:1

    Topics:

2019
Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
    European journal of medicinal chemistry, 2019, Jun-15, Volume: 172

    Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; MCF-7 Cells; Molecular Structure; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Sulfonamides

2019
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
    Bioorganic & medicinal chemistry, 2019, 05-15, Volume: 27, Issue:10

    Topics: Benzhydryl Compounds; Binding Sites; Cyclofenil; Down-Regulation; Estrogen Antagonists; Estrogen Receptor alpha; HEK293 Cells; Humans; Molecular Docking Simulation; Phenols; Protein Binding; Protein Structure, Tertiary; Structure-Activity Relationship

2019
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
    Journal of medicinal chemistry, 2019, 12-26, Volume: 62, Issue:24

    Topics: Animals; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation; Proteolysis; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Thiophenes; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019
Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer.
    Journal of medicinal chemistry, 2022, 03-10, Volume: 65, Issue:5

    Topics: Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Female; Humans; Receptors, Estrogen; Unfolded Protein Response

2022
Discovery of Thieno[2,3-
    Journal of medicinal chemistry, 2022, 04-14, Volume: 65, Issue:7

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor alpha; Female; Humans; Indazoles; MCF-7 Cells; Mice; Receptors, Estrogen; Thiophenes

2022
A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
    Molecular endocrinology (Baltimore, Md.), 1995, Volume: 9, Issue:8

    Topics: Amino Acid Sequence; Cell Division; Estradiol; Estradiol Congeners; Estrogen Antagonists; Fulvestrant; Growth Inhibitors; Humans; Molecular Sequence Data; Point Mutation; Polymorphism, Single-Stranded Conformational; Receptors, Estrogen; Recombinant Proteins; Structure-Activity Relationship; Tamoxifen; Transcriptional Activation; Transfection

1995
In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate.
    International journal of cancer, 1995, Sep-27, Volume: 63, Issue:1

    Topics: Animals; Arylsulfatases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Estrone; Female; Fulvestrant; Liver; Mammary Neoplasms, Experimental; Rats; Rats, Wistar; Steryl-Sulfatase; Sulfatases; Tamoxifen; Time Factors

1995
The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor.
    International journal of cancer, 1995, Aug-09, Volume: 62, Issue:4

    Topics: Binding Sites; Binding, Competitive; Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured

1995
Interaction of proteins with transcriptionally active estrogen receptors.
    Proceedings of the National Academy of Sciences of the United States of America, 1994, Oct-11, Volume: 91, Issue:21

    Topics: Animals; Base Sequence; Blotting, Western; Cell Line; Cell Nucleus; Cell-Free System; Chlorocebus aethiops; DNA Primers; DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Fulvestrant; Glutathione Transferase; HeLa Cells; Humans; Kidney; Molecular Sequence Data; Nuclear Proteins; Polyunsaturated Alkamides; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Transcription, Genetic

1994
Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
    British journal of cancer, 1994, Volume: 70, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Division; Clone Cells; Culture Media, Serum-Free; Drug Resistance; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Pleural Effusion, Malignant; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured

1994
The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling.
    Journal of cell science, 1993, Volume: 106 ( Pt 4)

    Topics: Amino Acid Sequence; Animals; Biological Transport; Cell Compartmentation; Cell Nucleus; Cells, Cultured; Chlorocebus aethiops; Cytoplasm; Estradiol; Estrogen Antagonists; Fulvestrant; Hybrid Cells; Mice; Molecular Sequence Data; Oligomycins; Polyunsaturated Alkamides; Receptors, Estrogen; Recombinant Proteins; Sequence Homology, Amino Acid; Tamoxifen; Transfection

1993
RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice.
    The Journal of steroid biochemistry and molecular biology, 1994, Volume: 48, Issue:2-3

    Topics: Animals; Antineoplastic Agents; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Progesterone; Rabbits; Rats; Receptors, Estrogen; Tamoxifen; Thymus Gland; Tumor Cells, Cultured; Uterus

1994
Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells.
    Biochemical pharmacology, 1994, Jan-20, Volume: 47, Issue:2

    Topics: Cell Division; Dose-Response Relationship, Drug; Estradiol; Fulvestrant; Humans; Oleic Acid; Oleic Acids; Receptors, Estrogen; Stearic Acids; Tamoxifen; Tumor Cells, Cultured

1994
Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.
    International journal of cancer, 1994, Jan-15, Volume: 56, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Cathepsin D; Cell Division; Drug Resistance; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Proteins; Receptors, Estrogen; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins

1994
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
    Cancer research, 1993, Jul-15, Volume: 53, Issue:14

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Resistance; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Mice; Mice, Nude; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured

1993
Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells.
    British journal of pharmacology, 1995, Volume: 116, Issue:5

    Topics: Base Sequence; Blotting, Western; Breast Neoplasms; Cell Division; Culture Media, Conditioned; DNA; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Insulin-Like Growth Factor I; Molecular Sequence Data; Polyunsaturated Alkamides; RNA, Messenger; Steroids; Tamoxifen; Tumor Cells, Cultured

1995
Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors.
    Biochemical and biophysical research communications, 1996, Mar-27, Volume: 220, Issue:3

    Topics: Breast Neoplasms; Cell Cycle; Cell Line; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Estradiol; Estradiol Congeners; Estrogen Antagonists; Female; Fulvestrant; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; RNA, Messenger; Simvastatin; Tamoxifen; Tumor Cells, Cultured

1996
Regulation of avian osteoclastic H+ -ATPase and bone resorption by tamoxifen and calmodulin antagonists. Effects independent of steroid receptors.
    The Journal of biological chemistry, 1996, May-24, Volume: 271, Issue:21

    Topics: Animals; Biological Transport; Bone Resorption; Calmodulin; Cell Membrane; Cells, Cultured; Chickens; Diethylstilbestrol; Drug Synergism; Estradiol; Female; Fulvestrant; Hydrochloric Acid; Osteoclasts; Proton-Translocating ATPases; Tamoxifen; Trifluoperazine

1996
The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens.
    Proceedings of the National Academy of Sciences of the United States of America, 1997, Mar-18, Volume: 94, Issue:6

    Topics: Animals; Base Sequence; Binding Sites; Breast Neoplasms; Cell Line; DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Enzymologic; Genes, Reporter; Genetic Vectors; Glutathione Transferase; Growth Hormone; Humans; Kinetics; Mice; Molecular Sequence Data; NAD(P)H Dehydrogenase (Quinone); Oligodeoxyribonucleotides; Promoter Regions, Genetic; Receptors, Estrogen; Recombinant Proteins; Tamoxifen; Transfection

1997
FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
    Molecular endocrinology (Baltimore, Md.), 1997, Volume: 11, Issue:7

    Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Diethylstilbestrol; DNA Nucleotidyltransferases; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Fulvestrant; Hexestrol; HSP90 Heat-Shock Proteins; Humans; Ligands; Molecular Sequence Data; Nafoxidine; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Time Factors; Yeasts

1997
Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.
    Molecular and cellular biology, 1997, Volume: 17, Issue:9

    Topics: Biomarkers, Tumor; Cell Differentiation; Cell Division; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Cyclins; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Oncogene Proteins; Pregnancy; Proto-Oncogene Proteins; Receptors, Estrogen; Tamoxifen; Transcription, Genetic

1997
Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains.
    Biochemical and biophysical research communications, 1997, Aug-28, Volume: 237, Issue:3

    Topics: Amino Acid Sequence; Animals; Base Sequence; Binding Sites; Enzyme Induction; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Integrases; Kinetics; Mice; Molecular Sequence Data; Mutagenesis, Insertional; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Point Mutation; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Teratoma; Tumor Cells, Cultured; Viral Proteins

1997
Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha.
    The Journal of biological chemistry, 1997, Oct-10, Volume: 272, Issue:41

    Topics: Animals; Cloning, Molecular; COS Cells; Dimerization; DNA; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Ligands; Polymerase Chain Reaction; Receptors, Estrogen; Tamoxifen; Temperature

1997
Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen.
    The Journal of clinical investigation, 1998, Jan-15, Volume: 101, Issue:2

    Topics: Blotting, Northern; Blotting, Western; Bone Morphogenetic Protein 6; Bone Morphogenetic Proteins; Cell Line; Estradiol; Estrogens; Fulvestrant; Humans; Osteoblasts; Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Transforming Growth Factor beta

1998
Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
    Cancer research, 1998, Jan-15, Volume: 58, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transforming Growth Factor beta; Tumor Cells, Cultured

1998
Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an breast tumor.
    International journal of oncology, 1998, Volume: 12, Issue:5

    Topics: Animals; Binding Sites; Breast Neoplasms; Cell Division; DNA Primers; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Glycine; Humans; Luciferases; Mice; Mice, Nude; Ovariectomy; Point Mutation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Valine

1998
The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.
    British journal of cancer, 1998, Volume: 77, Issue:11

    Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Transforming Growth Factor alpha

1998
Anti-estrogens induce apoptosis of multiple myeloma cells.
    Blood, 1998, Sep-01, Volume: 92, Issue:5

    Topics: Apoptosis; Breast Neoplasms; Cell Division; Cell Survival; Coloring Agents; Estradiol; Estrogen Antagonists; Flow Cytometry; Fulvestrant; Hematopoietic Stem Cells; Humans; Immunoblotting; Multiple Myeloma; Propidium; Receptors, Estrogen; Tamoxifen; Toremifene; Tumor Cells, Cultured

1998
Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins.
    Molecular endocrinology (Baltimore, Md.), 1998, Volume: 12, Issue:8

    Topics: Diethylstilbestrol; Dimerization; DNA Nucleotidyltransferases; Estradiol; Estrogen Antagonists; Fulvestrant; Hexestrol; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen

1998
Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:11

    Topics: Animals; Breast Neoplasms; Carrier Proteins; Cell Nucleus; Estradiol; Estrogen Antagonists; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins; Female; Fulvestrant; Genes, Tumor Suppressor; Growth Inhibitors; Half-Life; Humans; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Organ Culture Techniques; Pregnancy; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tamoxifen; Transcription, Genetic

1997
Transcriptional regulation by a naturally occurring truncated rat estrogen receptor (ER), truncated ER product-1 (TERP-1).
    Molecular endocrinology (Baltimore, Md.), 1999, Volume: 13, Issue:2

    Topics: Animals; Binding, Competitive; Blotting, Western; Chlorocebus aethiops; COS Cells; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Pituitary Gland; Plasmids; Precipitin Tests; Rats; Receptors, Estrogen; Tamoxifen

1999
Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors.
    Toxicology and applied pharmacology, 1999, Mar-15, Volume: 155, Issue:3

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Binding, Competitive; Breast Neoplasms; Cell Count; Cell Division; DNA, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Mice; Rats; Rats, Wistar; Receptors, Estrogen; Tamoxifen; Thymidine; Tumor Cells, Cultured; Uterus

1999
Differences in morphology and cytoskeleton of MCF-7 and MX-1 cells after therapy with OH-tamoxifen and the pure estrogen antagonist ZM 182780. An immunofluorescence and scanning electron microscopic study.
    Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft, 1999, Volume: 181, Issue:3

    Topics: Actins; Antineoplastic Agents; Breast Neoplasms; Cytoskeleton; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Immunohistochemistry; Keratins; Microscopy, Electron, Scanning; Receptors, Estrogen; Tamoxifen; Tubulin; Tumor Cells, Cultured; Vimentin

1999
Inhibition of estrogen receptor function promotes porcine coronary artery smooth muscle cell proliferation.
    Steroids, 1999, Volume: 64, Issue:7

    Topics: Animals; Base Sequence; Cell Division; DNA Primers; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Muscle, Smooth, Vascular; Receptors, Estrogen; RNA, Messenger; Swine; Tamoxifen; Tumor Cells, Cultured

1999
Comparative analyses of mechanistic differences among antiestrogens.
    Endocrinology, 1999, Volume: 140, Issue:12

    Topics: Blood Proteins; Breast Neoplasms; Cell Division; Cinnamates; Drug Stability; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression; Humans; Protein Binding; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Stilbenes; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured

1999
Differential cross-talk of estrogen and growth factor receptors in two human mammary tumor cell lines.
    The Journal of steroid biochemistry and molecular biology, 1999, Dec-31, Volume: 71, Issue:5-6

    Topics: Breast Neoplasms; Cell Division; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Insulin-Like Growth Factor I; Neuregulin-1; Receptors, Estrogen; Signal Transduction; Tamoxifen; Tumor Cells, Cultured

1999
Subnuclear trafficking of estrogen receptor-alpha and steroid receptor coactivator-1.
    Molecular endocrinology (Baltimore, Md.), 2000, Volume: 14, Issue:4

    Topics: Antibodies, Monoclonal; Binding Sites; Biological Transport; Cell Nucleus; Estradiol; Estrogen Receptor alpha; Fulvestrant; Gene Deletion; Green Fluorescent Proteins; HeLa Cells; Histone Acetyltransferases; Humans; Infant; Kinetics; Luminescent Proteins; Mutagenesis; Nuclear Matrix; Nuclear Receptor Coactivator 1; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Transcription Factors; Tumor Cells, Cultured

2000
Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
    Cancer research, 2000, Jun-15, Volume: 60, Issue:12

    Topics: Cell Culture Techniques; Cell Division; Cells, Cultured; Diethylstilbestrol; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens, Non-Steroidal; Fulvestrant; Humans; Male; Methylation; Oligonucleotides, Antisense; Prostate; Prostatic Neoplasms; Protein Biosynthesis; Proteins; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins

2000
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    Cancer research, 2000, Sep-15, Volume: 60, Issue:18

    Topics: Allosteric Regulation; Amino Acid Substitution; Aspartic Acid; Binding Sites; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Glycine; Humans; Kinetics; Ligands; Mutagenesis, Site-Directed; Protein Conformation; Protein Structure, Tertiary; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured

2000
Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells.
    American journal of physiology. Cell physiology, 2000, Volume: 279, Issue:5

    Topics: Animals; Cells, Cultured; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Ligands; Mammary Glands, Animal; Osteoblasts; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Response Elements; Tamoxifen

2000
Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain.
    Oncogene, 2000, Sep-28, Volume: 19, Issue:41

    Topics: Adenocarcinoma; Antigens, Polyomavirus Transforming; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cyclin D1; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; G1 Phase; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Structure, Tertiary; Recombinant Fusion Proteins; Retinoblastoma Protein; Tamoxifen; Transfection; Tumor Cells, Cultured

2000
FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent.
    Nature cell biology, 2001, Volume: 3, Issue:1

    Topics: Bacterial Proteins; Biological Transport; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dactinomycin; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; HeLa Cells; Histone Acetyltransferases; Humans; Leupeptins; Ligands; Luminescent Proteins; Microscopy, Fluorescence; Multienzyme Complexes; Nuclear Matrix; Nuclear Receptor Coactivator 1; Proteasome Endopeptidase Complex; Protein Structure, Tertiary; Receptors, Estrogen; Tamoxifen; Transcription Factors; Transcription, Genetic

2001
Regulation of the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells.
    The Journal of steroid biochemistry and molecular biology, 2000, Nov-15, Volume: 74, Issue:4

    Topics: Breast Neoplasms; Deoxyribonuclease I; DNA; DNA Footprinting; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; Proteins; Response Elements; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins

2000
Differential activation of wild-type and variant forms of estrogen receptor alpha by synthetic and natural estrogenic compounds using a promoter containing three estrogen-responsive elements.
    The Journal of steroid biochemistry and molecular biology, 2001, Volume: 78, Issue:1

    Topics: Benzhydryl Compounds; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Estrogens, Non-Steroidal; Fulvestrant; Humans; Phenols; Polychlorinated Biphenyls; Polymorphism, Genetic; Receptors, Estrogen; Response Elements; Tamoxifen; Transfection; Tumor Cells, Cultured

2001
Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling.
    Journal of molecular endocrinology, 2001, Volume: 27, Issue:3

    Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured

2001
Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera.
    Oncogene, 2002, Jul-25, Volume: 21, Issue:32

    Topics: Amino Acid Sequence; Animals; Antibodies; Breast Neoplasms; COS Cells; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Humans; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Phosphorylation; Protein Serine-Threonine Kinases; Receptors, Estrogen; Serine; Signal Transduction; Tamoxifen

2002
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer.
    Breast cancer (Tokyo, Japan), 2002, Volume: 9, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Lymphokines; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells.
    Biochimica et biophysica acta, 2002, Oct-11, Volume: 1578, Issue:1-3

    Topics: Blotting, Western; Cell Nucleus; Chromatin; Deoxyribonuclease I; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation; Humans; Immunohistochemistry; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Proteins; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins

2002
Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Molecular endocrinology (Baltimore, Md.), 2003, Volume: 17, Issue:5

    Topics: Base Composition; Base Sequence; Binding Sites; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Fulvestrant; Gene Expression Regulation; Molecular Sequence Data; Point Mutation; Promoter Regions, Genetic; Protein Structure, Tertiary; Receptors, Estrogen; Sp1 Transcription Factor; Tamoxifen; Tumor Cells, Cultured; Zinc Fingers

2003
Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
    Molecular endocrinology (Baltimore, Md.), 2003, Volume: 17, Issue:7

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Breast Neoplasms; DNA Damage; DNA Repair; DNA-Binding Proteins; Enzyme Activation; Epithelial Cells; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Guanine; Humans; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Xeroderma Pigmentosum Group A Protein

2003
Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation.
    The Journal of biological chemistry, 2003, Jul-18, Volume: 278, Issue:29

    Topics: Amino Acid Substitution; Base Sequence; Binding Sites; DNA; Estradiol; Estrogen Receptor alpha; Fulvestrant; HeLa Cells; Humans; In Vitro Techniques; Leucine; Ligands; Models, Molecular; Mutagenesis, Site-Directed; Promoter Regions, Genetic; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Transcription Factor AP-1; Transcriptional Activation; Two-Hybrid System Techniques

2003
Antiestrogens are pro-apoptotic in normal human breast epithelial cells.
    International journal of cancer, 2003, Jul-10, Volume: 105, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Breast; Breast Neoplasms; Caspase 3; Caspases; Cells, Cultured; Enzyme Induction; Epithelial Cells; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, p53; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Stimulation, Chemical; Tamoxifen; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2003
Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer
    Molecular endocrinology (Baltimore, Md.), 2003, Volume: 17, Issue:10

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Ligands; MAP Kinase Kinase Kinases; Multienzyme Complexes; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Receptors, Estrogen; Tamoxifen; Transcription, Genetic

2003
p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Cancer research, 2003, Aug-01, Volume: 63, Issue:15

    Topics: Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p27; DNA-Binding Proteins; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Growth Substances; Humans; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Co-Repressor 2; Receptors, Estrogen; Repressor Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Proteins

2003
Identification of estrogen receptor beta expression in Chinese hamster ovary (CHO) cells and comparison of estrogen-responsive gene transcription in cells adapted to serum-free media.
    The Journal of steroid biochemistry and molecular biology, 2003, Volume: 86, Issue:1

    Topics: Animals; CHO Cells; Cricetinae; Culture Media, Serum-Free; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Ethanol; Fulvestrant; Gene Expression Regulation; Genes, Reporter; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; RNA, Messenger; Tamoxifen; Transcription, Genetic

2003
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
    Endocrinology, 2003, Volume: 144, Issue:11

    Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Combinations; Drug Resistance; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tamoxifen

2003
Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1.
    Molecular endocrinology (Baltimore, Md.), 2004, Volume: 18, Issue:2

    Topics: Breast Neoplasms; Cycloheximide; DNA-Binding Proteins; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Galactosyltransferases; Gene Expression Regulation; Humans; Insulin-Like Growth Factor Binding Protein 4; Neoplasm Proteins; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Pesticides; Phytoestrogens; Protein Synthesis Inhibitors; Puromycin; Receptors, Estrogen; Regulatory Factor X Transcription Factors; Tamoxifen; Transcription Factors; Tumor Cells, Cultured; X-Box Binding Protein 1

2004
Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells.
    Molecular endocrinology (Baltimore, Md.), 2004, Volume: 18, Issue:7

    Topics: Breast Neoplasms; Cell Proliferation; Cyclin A; DNA-Binding Proteins; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Mutation; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Smad2 Protein; Smad3 Protein; Smad4 Protein; Tamoxifen; Trans-Activators; Transforming Growth Factor beta; Tumor Cells, Cultured

2004
Re-expression of estrogen receptor alpha using a tetracycline-regulated gene expression system induced estrogen-mediated growth inhibition of the MDA-MB-231 breast cancer cell line.
    Biochemistry and cell biology = Biochimie et biologie cellulaire, 2004, Volume: 82, Issue:2

    Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Chloramphenicol O-Acetyltransferase; Clone Cells; Doxycycline; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; S Phase; Tamoxifen; Transfection

2004
Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation.
    Journal of molecular endocrinology, 2004, Volume: 32, Issue:2

    Topics: Breast Neoplasms; Cell Proliferation; Cell Transformation, Neoplastic; Cycloheximide; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Time Factors; Tumor Cells, Cultured

2004
Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
    Journal of molecular endocrinology, 2004, Volume: 32, Issue:2

    Topics: Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrrolidines; Raloxifene Hydrochloride; Response Elements; Tamoxifen; Thiophenes; Transcription, Genetic; Tumor Cells, Cultured

2004
Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Aug-01, Volume: 10, Issue:15

    Topics: Apoptosis; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Coloring Agents; DNA Fragmentation; Drug Resistance, Neoplasm; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Fulvestrant; G1 Phase; Hormone Antagonists; Humans; Immunoblotting; Mifepristone; Phosphorylation; Receptors, Estrogen; Receptors, Progesterone; Resting Phase, Cell Cycle; Tamoxifen; Tetrazolium Salts; Thiazoles; Time Factors

2004
Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells.
    The Journal of biological chemistry, 2005, Mar-04, Volume: 280, Issue:9

    Topics: Angiogenesis Inhibitors; Animals; Aorta; Blotting, Western; Cattle; Cell Nucleus; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Flavonoids; Fulvestrant; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mice; Microcirculation; Models, Biological; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phenols; Phosphorylation; Polyphenols; Resveratrol; Serine; Signal Transduction; Stilbenes; Tamoxifen; Time Factors; Transfection; Umbilical Veins; Wine

2005
A nongenomic action of 17beta-estradiol as the mechanism underlying the acute suppression of secretion of luteinizing hormone.
    Biology of reproduction, 2005, Volume: 73, Issue:1

    Topics: Animals; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Hormone Antagonists; Kinetics; Luteinizing Hormone; Nitriles; Phenols; Pituitary Gland, Anterior; Propionates; Pyrazoles; Secretory Rate; Sheep; Tamoxifen

2005
Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-alpha expression in the rat uterus.
    Anti-cancer drugs, 2005, Volume: 16, Issue:5

    Topics: Animals; Blotting, Northern; Blotting, Western; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Immunohistochemistry; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus

2005
Diffusion-time distribution analysis reveals characteristic ligand-dependent interaction patterns of nuclear receptors in living cells.
    Biochemistry, 2005, Sep-06, Volume: 44, Issue:35

    Topics: Bacterial Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Diffusion; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Ligands; Luminescent Proteins; Recombinant Fusion Proteins; Spectrometry, Fluorescence; Tamoxifen; Trans-Activators; Transfection; Tumor Cells, Cultured

2005
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
    Breast cancer research : BCR, 2006, Volume: 8, Issue:1

    Topics: Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Ibandronic Acid; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured

2006
AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines.
    BMC cancer, 2006, May-02, Volume: 6

    Topics: Acetyltransferases; Alleles; Breast Neoplasms; Cell Line, Tumor; Cloning, Molecular; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Receptor Coactivator 3; Oncogene Proteins; Peptides; Polymerase Chain Reaction; Pyrrolidines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Sequence Analysis, DNA; Tamoxifen; Thiophenes; Trans-Activators

2006
Ligand-selective interdomain conformations of estrogen receptor-alpha.
    Molecular endocrinology (Baltimore, Md.), 2007, Volume: 21, Issue:1

    Topics: Cell Line, Tumor; Cell Nucleus; Dimerization; DNA; Estradiol; Estrogen Receptor alpha; Estrogens; Fluorescence Resonance Energy Transfer; Fulvestrant; Humans; Kinetics; Ligands; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Tamoxifen

2007
Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Cancer research, 2006, Oct-15, Volume: 66, Issue:20

    Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chickens; COUP Transcription Factor II; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Receptors, Progesterone; Tamoxifen; Transcription, Genetic; Transfection

2006
Molecular cloning and characterization of the human WISP-2/CCN5 gene promoter reveal its upregulation by oestrogens.
    The Journal of endocrinology, 2006, Volume: 191, Issue:3

    Topics: 5' Flanking Region; Base Sequence; Blotting, Western; Breast Neoplasms; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Cloning, Molecular; CREB-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Intercellular Signaling Peptides and Proteins; Molecular Sequence Data; Neoplasm Proteins; Promoter Regions, Genetic; Repressor Proteins; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Transcription Factors; Transcription, Genetic; Transfection

2006
Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
    International journal of oncology, 2007, Volume: 30, Issue:2

    Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Prohibitins; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Uterine Neoplasms

2007
Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
    Maturitas, 2007, May-20, Volume: 57, Issue:1

    Topics: Breast Neoplasms; Carcinoma; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured; Up-Regulation

2007
Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line.
    Journal of cellular physiology, 2007, Volume: 212, Issue:3

    Topics: Animals; Blotting, Western; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Gonadotrophs; HeLa Cells; Humans; Insulin-Like Growth Factor I; Luciferases; Mice; Mice, Inbred C57BL; Phosphorylation; Promoter Regions, Genetic; Receptor Cross-Talk; Receptor, IGF Type 1; RNA, Messenger; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Transcription, Genetic; Transfection

2007
Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death.
    Steroids, 2007, Volume: 72, Issue:11-12

    Topics: Caspase 3; Caspase 9; Cell Death; Enzyme Activation; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Flavonoids; Fulvestrant; HeLa Cells; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Receptors, Estrogen; Tamoxifen; Time Factors

2007
Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.
    International journal of cancer, 2008, Apr-01, Volume: 122, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Blotting, Southern; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; DNA, Mitochondrial; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Ethidium; Female; Flow Cytometry; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen

2008
Distribution plasticity of the human estrogen receptor alpha in live cells: distinct imaging of consecutively expressed receptors.
    Journal of molecular biology, 2007, Dec-14, Volume: 374, Issue:5

    Topics: Animals; Blotting, Western; CHO Cells; Cricetinae; Cricetulus; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; Microscopy, Confocal; Microscopy, Fluorescence; Spectrometry, Fluorescence; Subcellular Fractions; Tamoxifen

2007
Human prolactin gene promoter regulation by estrogen: convergence with tumor necrosis factor-alpha signaling.
    Endocrinology, 2008, Volume: 149, Issue:2

    Topics: Animals; Cell Line; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression Regulation; Humans; Luciferases; Pituitary Gland, Anterior; Prolactin; Promoter Regions, Genetic; Rats; Rats, Inbred F344; Receptors, Estrogen; Signal Transduction; Tamoxifen; Tumor Necrosis Factor-alpha

2008
Tamoxifen stimulates calcium entry into human platelets.
    Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:4

    Topics: Adenosine Diphosphate; Adult; Blood Platelets; Calcium; Calcium Signaling; Diethylstilbestrol; Drug Synergism; Estradiol; Estrenes; Estrogen Antagonists; Ethamoxytriphetol; Female; Fulvestrant; Humans; Male; Middle Aged; Molecular Structure; Phosphodiesterase Inhibitors; Pyrrolidinones; Stilbenes; Structure-Activity Relationship; Tamoxifen; Thrombin; Vasopressins

2007
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
    Journal of molecular endocrinology, 2009, Volume: 42, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fetal Proteins; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Microtubule-Associated Proteins; Middle Aged; Models, Biological; Neoplasm Proteins; Nephroblastoma Overexpressed Protein; Nuclear Proteins; Phenotype; Prognosis; Recurrence; RNA, Messenger; Securin; Tamoxifen

2009
Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.
    Endocrinology, 2009, Volume: 150, Issue:5

    Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Receptors, Estrogen; Tamoxifen; Tissue Distribution; Tumor Cells, Cultured

2009
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells.
    Nucleic acids research, 2009, Volume: 37, Issue:8

    Topics: 3' Untranslated Regions; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cycloheximide; Dactinomycin; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; MicroRNAs; Nucleic Acid Synthesis Inhibitors; Promoter Regions, Genetic; Protein Synthesis Inhibitors; ras GTPase-Activating Proteins; RNA-Binding Proteins; RNA, Antisense; Tamoxifen

2009
Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
    Breast cancer research and treatment, 2010, Volume: 120, Issue:3

    Topics: Adenocarcinoma; Amino Acid Motifs; Amino Acid Substitution; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Point Mutation; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Recombinant Fusion Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factor AP-1; Transfection

2010
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells.
    American journal of respiratory cell and molecular biology, 2010, Volume: 42, Issue:3

    Topics: Adenocarcinoma; Cell Line, Tumor; Cell Nucleus; Cyclin D1; Enzyme Activation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fluorescence; Fulvestrant; Genome, Human; Humans; Lung Neoplasms; Male; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Mutant Proteins; Phosphoserine; Protein Transport; Sex Characteristics; Signal Transduction; Subcellular Fractions; Tamoxifen

2010
4-Hydroxytamoxifen inhibits K(+) currents in mouse ventricular myocytes.
    European journal of pharmacology, 2010, Mar-10, Volume: 629, Issue:1-3

    Topics: Animals; Dactinomycin; Electric Conductivity; Estradiol; Female; Fulvestrant; Heart Ventricles; Kinetics; Mice; Muscle Cells; Patch-Clamp Techniques; Potassium; Receptors, Estrogen; Tamoxifen; Transcription, Genetic

2010
Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
    Cancer biology & therapy, 2010, Mar-01, Volume: 9, Issue:5

    Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Keratins; Oligonucleotides; Proteasome Endopeptidase Complex; Receptors, Estrogen; Tamoxifen

2010
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
    Cancer research, 2010, Mar-01, Volume: 70, Issue:5

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fibroblast Growth Factor 2; Fulvestrant; Gene Amplification; Gene Silencing; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Phosphorylation; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Estrogen; RNA, Messenger; Tamoxifen

2010
Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.
    International journal of oncology, 2010, Volume: 36, Issue:5

    Topics: Carcinoma; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Phosphorylation; Raloxifene Hydrochloride; RNA, Small Interfering; Signal Transduction; Tamoxifen; Thyroid Neoplasms

2010
Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression.
    PloS one, 2010, Jun-08, Volume: 5, Issue:6

    Topics: Base Sequence; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Culture Media; DNA Primers; Estradiol; Estrogen Receptor Modulators; Estrogens; Flow Cytometry; Fulvestrant; Humans; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen

2010
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
    International journal of cancer, 2011, Apr-15, Volume: 128, Issue:8

    Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Flow Cytometry; Fulvestrant; Humans; Immunoenzyme Techniques; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tamoxifen; Tumor Suppressor Protein p53

2011
Ligands specify estrogen receptor alpha nuclear localization and degradation.
    BMC cell biology, 2010, Dec-10, Volume: 11

    Topics: Cell Line, Tumor; Digitonin; Estradiol; Estrogen Receptor alpha; Fulvestrant; Green Fluorescent Proteins; Humans; Ligands; Microscopy, Immunoelectron; Proteasome Endopeptidase Complex; Recombinant Fusion Proteins; RNA, Messenger; Tamoxifen

2010
High content imaging-based assay to classify estrogen receptor-α ligands based on defined mechanistic outcomes.
    Gene, 2011, May-15, Volume: 477, Issue:1-2

    Topics: Benzhydryl Compounds; Blotting, Western; Cell Line, Tumor; Cluster Analysis; Endocrine Disruptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Green Fluorescent Proteins; HeLa Cells; Humans; Microscopy, Fluorescence; Phenols; Principal Component Analysis; Promoter Regions, Genetic; Raloxifene Hydrochloride; Reproducibility of Results; Tamoxifen

2011
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Cancer science, 2011, Volume: 102, Issue:11

    Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays

2011
Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoid synthesis.
    Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:6

    Topics: Animals; Antineoplastic Agents, Hormonal; Aorta, Thoracic; Estradiol; Fulvestrant; Indomethacin; Male; NG-Nitroarginine Methyl Ester; Prostaglandins; Rats; Rats, Wistar; Tamoxifen; Vasodilation

2011
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
    Cancer research, 2011, Dec-15, Volume: 71, Issue:24

    Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oligonucleotide Array Sequence Analysis; Pyrazoles; Receptor, IGF Type 1; Receptor, Insulin; Tamoxifen; Triazines; Triazoles; Xenograft Model Antitumor Assays

2011
Nanomolar dose of bisphenol A rapidly modulates spinogenesis in adult hippocampal neurons.
    Molecular and cellular endocrinology, 2012, Apr-04, Volume: 351, Issue:2

    Topics: Animals; Benzhydryl Compounds; Dendritic Spines; Dizocilpine Maleate; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Flavonoids; Fulvestrant; Hippocampus; Humans; Male; Mitogen-Activated Protein Kinases; Neurons; Phenols; Rats; Rats, Wistar; Receptors, Estrogen; Receptors, N-Methyl-D-Aspartate; Tamoxifen

2012
Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.
    Molecular endocrinology (Baltimore, Md.), 2012, Volume: 26, Issue:7

    Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Humans; MCF-7 Cells; Protein Conformation; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic

2012
Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells.
    The Journal of steroid biochemistry and molecular biology, 2012, Volume: 132, Issue:1-2

    Topics: Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Humans; Ovarian Neoplasms; RNA, Messenger; Signal Transduction; Tamoxifen

2012
Development of a novel molecular sensor for imaging estrogen receptor-coactivator protein-protein interactions.
    PloS one, 2012, Volume: 7, Issue:8

    Topics: Animals; Biosensing Techniques; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Genes, Reporter; Genetic Complementation Test; Humans; Imaging, Three-Dimensional; Luciferases; Mice; Mice, Inbred BALB C; Mutation; Nuclear Receptor Coactivator 3; Protein Binding; Protein Structure, Secondary; Protein Structure, Tertiary; Recombinant Fusion Proteins; Tamoxifen; Time Factors

2012
Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
    Hormones & cancer, 2013, Volume: 4, Issue:1

    Topics: Apoptosis; Carcinoma, Transitional Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Immediate-Early Proteins; MCF-7 Cells; Poly(ADP-ribose) Polymerases; Raloxifene Hydrochloride; S-Phase Kinase-Associated Proteins; Tamoxifen; Tumor Suppressor Proteins; Urinary Bladder Neoplasms

2013
Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha.
    BMC structural biology, 2013, Oct-25, Volume: 13

    Topics: Animals; Binding Sites; Diethylstilbestrol; Dimerization; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; Hydrogen Bonding; Ligands; Models, Molecular; Molecular Dynamics Simulation; Phytoestrogens; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Resveratrol; Stilbenes; Tamoxifen

2013
Estradiol regulates Tumor Necrosis Factor-α expression and secretion in Estrogen Receptor positive breast cancer cells.
    Molecular and cellular endocrinology, 2014, Aug-25, Volume: 394, Issue:1-2

    Topics: Cell Line, Tumor; Chromatin Immunoprecipitation; Epithelial Cells; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mammary Glands, Human; Promoter Regions, Genetic; Protein Binding; RNA, Messenger; Signal Transduction; Tamoxifen; Tumor Necrosis Factor-alpha

2014
Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant.
    Chemico-biological interactions, 2014, Sep-05, Volume: 220

    Topics: Cell Line; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Regulation; Humans; Inhibitory Concentration 50; Microarray Analysis; Protein Binding; Receptors, Estrogen; Tamoxifen

2014
Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
    Breast cancer (Tokyo, Japan), 2016, Volume: 23, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Furans; Humans; Ketones; Neoplastic Stem Cells; Tamoxifen

2016
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Breast cancer research : BCR, 2015, Feb-25, Volume: 17

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression; Gene Expression Profiling; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Ligands; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transcriptome; Xenograft Model Antitumor Assays

2015
Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis.
    Journal of pharmacological sciences, 2015, Volume: 128, Issue:3

    Topics: Catalysis; Cytosol; Estradiol; Fulvestrant; Hep G2 Cells; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Sulfates; Sulfotransferases; Tamoxifen

2015
Effect of tamoxifen and fulvestrant long-term treatments on ROS production and (pro/anti)-oxidant enzymes mRNA levels in a MCF-7-derived breast cancer cell line.
    Breast cancer (Tokyo, Japan), 2016, Volume: 23, Issue:5

    Topics: Antineoplastic Agents, Hormonal; Antioxidants; Cell Line, Tumor; Cyclic N-Oxides; Enzymes; Estradiol; Fulvestrant; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kelch-Like ECH-Associated Protein 1; MCF-7 Cells; NADPH Oxidases; Reactive Oxygen Species; Spin Labels; Tamoxifen

2016
Selective estrogen receptor modulators and betulinic acid act synergistically to target ERα and SP1 transcription factor dependent Pygopus expression in breast cancer.
    Journal of clinical pathology, 2016, Volume: 69, Issue:6

    Topics: Antineoplastic Agents; Betulinic Acid; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Hydroxytestosterones; Intracellular Signaling Peptides and Proteins; Microarray Analysis; Pentacyclic Triterpenes; Promoter Regions, Genetic; Selective Estrogen Receptor Modulators; Signal Transduction; Sp1 Transcription Factor; Tamoxifen; Triterpenes

2016
Improved specificity of hippocampal memory trace labeling.
    Hippocampus, 2016, Volume: 26, Issue:6

    Topics: Animals; Bacterial Proteins; Cell Count; Channelrhodopsins; Conditioning, Psychological; Estradiol; Fear; Fulvestrant; Hippocampus; Immunohistochemistry; Luminescent Proteins; Memory; Mice, Transgenic; Microscopy, Confocal; Models, Animal; Neurons; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Untranslated; Selective Estrogen Receptor Modulators; Tamoxifen

2016
Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.
    Scientific reports, 2016, 10-07, Volume: 6

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mutation; Progestins; Tamoxifen; Unfolded Protein Response

2016
In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
    Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:6

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Computer Simulation; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mitoxantrone; Neoplasm Metastasis; Reproducibility of Results; Tamoxifen; Thioridazine

2018
Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor.
    Medical oncology (Northwood, London, England), 2021, Jan-15, Volume: 38, Issue:1

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crizotinib; Drug Synergism; Estrogen Receptor alpha; Fulvestrant; Humans; Inhibitory Concentration 50; Ki-67 Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Tamoxifen

2021
Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
    Molecular cancer research : MCR, 2021, Volume: 19, Issue:6

    Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Models, Biological; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen

2021
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
    Journal of medicinal chemistry, 2016, 09-08, Volume: 59, Issue:17

    Topics: Administration, Oral; Animals; Biological Availability; Boronic Acids; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Mice, Inbred C57BL; Selective Estrogen Receptor Modulators; Signal Transduction; Stereoisomerism; Sterols; Tamoxifen

2016
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
    Journal of medicinal chemistry, 2020, 07-09, Volume: 63, Issue:13

    Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models, Molecular; Piperazines; Protein Domains; Pyridines; Pyridones; Receptors, Estrogen; Tissue Distribution; Transcription Factors; Xenograft Model Antitumor Assays

2020
Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
    European journal of medicinal chemistry, 2021, Oct-05, Volume: 221

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Estrogen Receptor Antagonists; Female; Humans; MCF-7 Cells; Molecular Structure; Receptors, Estrogen; Structure-Activity Relationship; Thiophenes; Tumor Cells, Cultured

2021
Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
    European journal of medicinal chemistry, 2020, Apr-15, Volume: 192

    Topics: Alkenes; Animals; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Cyclofenil; Dose-Response Relationship, Drug; Down-Regulation; Drug Development; Estrogen Receptor Antagonists; Humans; Molecular Structure; Receptors, Estrogen; Structure-Activity Relationship

2020